Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. SeaWorld (SEAS) upgraded to Neutral from Underperform at Macquarie with analyst Matthew Brooks saying management is executing well, 1H 2018 attendance growth was impressive, and a new 2020 EBITDA goal heading into a seasonally strong period changes is cautious thesis. 2. Alnylam (ALNY) upgraded to Buy from Hold at Stifel with analyst Paul Matteis citing a series of upcoming, likely positive pipeline events for givosiran, lumasiran and ALN-TTRsc02 along with his confidence in Alnylam's ability to have a dominant position in the TTR amyloidosis market over the longer-term. 3. NeoPhotonics (NPTN) upgraded to Buy from Neutral at B. Riley FBR with analyst Dave Kang saying he sees improving fundamentals and increased his estimates following the company's Q2 results. 4. Illumina (ILMN) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Steve Beuchaw saying his prior thesis overestimated the impact of new products such as NovaSeq on utilization of the legacy installed base and failed to value critical new markets. 5. MasTec (MTZ) upgraded to Outperform from Neutral at Baird with analyst Andrew Wittmann saying concerns of weak cash flow and the MVP project work stoppage have already been priced into the stock and now offer a potential catalyst for the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).